Patients Fought to Use This Blood-Drawing Robot with Toon Overbeeke

In this episode of The Crux of MedTech, Henry Norton sits down with Toon Overbeeke, CEO and Co-founder of Vitestro, the company behind the world's first CE-marked autonomous robotic phlebotomy device, Aletta. Fresh off a $70M oversubscribed Series B backed by Labcorp, Mayo Clinic, Sutter Health and Sonder Capital, with Intuitive Surgical founder Fred Moll on the board, Toon shares how a friend's father struggling through chemotherapy blood draws sparked the idea to automate the most commonly performed invasive procedure on the planet.Toon breaks down how Vitestro approached the problem from a business case first, not an engineering push, and why that distinction has kept their thesis intact for nine years. He shares surprising patient adoption data, including the counterintuitive finding that elderly patients are more willing to use the system than younger ones, and the moment a waiting room fight broke out because patients wanted to skip the line to use their robot.He also opens up about the personal evolution required to scale from a two-person team to over 100 FTEs, the trade-offs of managing long-standing team members through company growth, and how having Fred Moll and strategic investors on the cap table has accelerated their journey toward European commercial launch.Key Topics:The origin of Vitestro and why business case came before engineeringAutonomous robotic blood drawing and the Aletta devicePatient adoption data and the counterintuitive age findingsScaling from prototype to product and the factor-10 ruleBuilding a strategic investor base and cap table strategyPreparing for European commercial launchRelated Insights:Why standardising the pre-analytical phase matters for diagnostic accuracyHow a one-to-many supervision model makes autonomous devices commercially viableThe role of strategic investors like Labcorp and Mayo Clinic in de-risking commercialisationCore Challenges:Blood drawing remains the only part of the diagnostic chain that hasn't been automated, creating a bottleneck driven by staffing shortages, high turnover, and inconsistent quality that leads to hemolysis and rejected samples.Scaling from a working prototype to a reliable, serviceable, manufacturable medical device requires orders of magnitude more engineering and operations effort than most founders anticipate, encompassing everything from cyber security compliance and regulatory approvals to remote access infrastructure and field serviceability.Tune in now to hear how Vitestro is automating the world's most common invasive procedure and what it takes to build a medtech company from first principle to commercial launch.The Crux of MedTech podcast is brought to you by Cruxx, a specialist surgical robotics recruitment agency. To learn more about Cruxx,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠click here.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠A big thank you to our sponsors on this season of the podcast; ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ With a 35-year track record, TTP excels in turning innovative ideas into market-ready solutions. Their team of 300+ experts deliver breakthrough solutions in areas ranging from endoluminal robotics and navigation systems to ultrasound imaging. Whether you're a startup or a multinational, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP plc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ can accelerate your development with the latest technologies. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TTP.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠